Takeda Settles Actos Bladder Cancer Lawsuits for $2.4 Billion
The Japanese drug company agreed to pay $2.37 billion to plaintiffs who claimed the companys blockbuster Type 2 diabetes drug, Actos (pioglitazone), gave them bladder cancer. Complaints also said that the company hid the risk from patients and doctors and failed to warn the public. Actos is prescribed to type 2 diabetics and has been subject to massive litigation and billion-dollar verdicts.…Read More